1. Home
  2. PMEC vs TVRD Comparison

PMEC vs TVRD Comparison

Compare PMEC & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Primech Holdings Ltd.

PMEC

Primech Holdings Ltd.

HOLD

Current Price

$0.60

Market Cap

23.4M

Sector

N/A

ML Signal

HOLD

Logo Tvardi Therapeutics Inc.

TVRD

Tvardi Therapeutics Inc.

HOLD

Current Price

$1.06

Market Cap

27.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMEC
TVRD
Founded
1984
2017
Country
Singapore
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.4M
27.5M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
PMEC
TVRD
Price
$0.60
$1.06
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
★ $29.50
AVG Volume (30 Days)
91.8K
★ 159.9K
Earning Date
07-24-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 79.01
EPS
★ N/A
N/A
Revenue
N/A
★ $911,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 959.30
52 Week Low
$0.31
$0.93
52 Week High
$2.44
$43.65

Technical Indicators

Market Signals
Indicator
PMEC
TVRD
Relative Strength Index (RSI) 62.32 24.12
Support Level $0.51 N/A
Resistance Level $0.81 $2.02
Average True Range (ATR) 0.08 0.12
MACD 0.01 -0.03
Stochastic Oscillator 67.11 8.72

Price Performance

Historical Comparison
PMEC
TVRD

About PMEC Primech Holdings Ltd.

Primech Holdings Ltd is a Singapore-based facilities services and AI robotics group with operations in Singapore and Hong Kong. Through its subsidiaries, the company provides integrated facilities management, cleaning and stewarding services to the public and private sectors, serving airports, educational institutions, healthcare facilities, commercial buildings and hospitality venues. It also develops HYTRON, an autonomous restroom-cleaning robot that uses AI perception and robotic manipulation. In addition, the company operates HomeHelpy, a digital platform for booking home services for consumers.

About TVRD Tvardi Therapeutics Inc.

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Share on Social Networks: